Table 1.
Patient and tumor characteristics.
| Characteristic | nCRT (n = 113) | iCT (n = 23) | pCT (n = 30) |
|---|---|---|---|
| Sex, n (%) | |||
| Male | 91 (80.5%) | 16 (69.6%) | 29 (96.7%) |
| Age, years (median and range) | 63 (39–82) | 64 (52–77) | 64 (47–76) |
| Tumor type | |||
| Adenocarcinoma | 90 (79.6%) | 13 (56.5%) | 24 (80.0%) |
| Squamous cell carcinoma | 22 (19.5%) | 9 (39.1%) | 6 (20.0%) |
| Other + | 1 (0.9%) | 1 (4.3%) | |
| Histopathological grading | |||
| G1 | 3 (2.5%) | 0 | 2 (6.7%) |
| G2 | 51 (45.1%) | 7 (30.4%) | 5 (16.7%) |
| G3 | 32 (28.3%) | 10 (43.5%) | 13 (43.3%) |
| G4 | 1 (0.9%) | 0 | 0 |
| Gx or Missing | 26 (23.0%) | 6 (26.1%) | 10 (33.3%) |
| Tumor localization | |||
| Proximal | 0 | 2 (8.7%) | 0 |
| Middle | 18 (15.9%) | 5 (21.7%) | 4 (13.3%) |
| Distal | 80 (70.8%) | 10 (43.5%) | 19 (63.3%) |
| Gastro-esophageal junction | 15 (13.3%) | 6 (26.1%) | 7 (23.3%) |
| Clinical T stage | |||
| cT1 | 4 (3.5%) * | 0 | 0 |
| cT2 | 26 (23.0%) * | 0 | 2 (6.7%) |
| cT3 | 80 (70.8%) * | 17 (73.9%) | 16 (53.3%) |
| cT4 | 3 (2.7%) * | 5 (21.7%) | 3 (10.0%) |
| Missing | 0 | 1 (4.3%) | 9 (30.0%) |
| Clinical N stage | |||
| N0 | 35 (31.0%) # | 3 (13.0%) | 3 (10.0%) |
| N1 | 41 (36.3%) # | 5 (21.7%) | 6 (20.0%) |
| N2 | 34 (30.1%) # | 11 (47.8%) | 10 (33.3%) |
| N3 | 3 (2.7%) # | 4 (17.4%) | 5 (16.7%) |
| Missing | 0 | 0 | 6 (20.0%) |
| Clinical M stage | |||
| M0 | 113 (100%) | 21 (91.3%) | 2 (6.7%) |
| M1 | 0 | 2 (8.7%) ^ | 28 (93.3%) |
| TREATMENT REGIMEN | |||
| Neoadjuvant chemoradiotherapy | 113 (100%) | X | X |
| 4 courses of Paclitaxel | 3 (2.7%) | X | X |
| 5 courses of Paclitaxel | 109 (96.5%) | X | X |
| 6 courses of Paclitaxel | 1 (0.9%) | X | X |
| Induction or palliative chemotherapy | X | 23 (100%) | 30 (100%) |
| 6 courses of Paclitaxel | X | 8 (34.8%) | 13 (43.3%) |
| 6 + 3 courses of Paclitaxel | X | 15 (65.2%) | 17 (56.7%) |
| Resection | 113 (100%) | 11 (47.8%) | X |
| Other treatment | X | X | 1 (3.3%) £ |
Abbreviations: nCRT: neoadjuvant chemoradiotherapy, iCT: induction chemotherapy, pCT: palliative chemotherapy. + Other: neuroendocrine tumor. * uTstage (endosonography) in patients treated with neoadjuvant chemoradiotherapy. # uNstage (endosonography) in patients treated with neoadjuvant chemoradiotherapy. $ no location possible due to only radiological diagnostics. ^ Submucosal metastasis and suspicion of lung metastasis. £ brachytherapy.